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The Strength of Synergistic Interaction between Posaconazole and
Caspofungin Depends on the Underlying Azole Resistance Mechanism
of Aspergillus fumigatus
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Department of Medical Microbiology, Radboud University Medical Centre of Nijmegen, Nijmegen, The Netherlandsa; Clinical Microbiology Laboratory, Attikon University
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The majority of azole resistance mechanisms in Aspergillus fumigatus correspond to mutations in the cyp51A gene. As azoles are
less effective against infections caused by multiply azole-resistant A. fumigatus isolates, new therapeutic options are warranted
for treating these infections. We therefore investigated the in vitro combination of posaconazole (POSA) and caspofungin (CAS)
against 20 wild-type and resistant A. fumigatus isolates with 10 different resistance mechanisms. Fungal growth was assessed
with the XTT [2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt] method. Pharmacody-
namic interactions were assessed with the fractional inhibitory concentration (FIC) index (FICi) on the basis of 10% (FICi-0),
25% (FICi-1), or 53 0% (FICi-2) growth, and FICs were correlated with POSA and CAS concentrations. Synergy and antagonism
were concluded when the FICi values were statistically significantly (t test, P< 0.05) lower than 1 and higher than 1.25, respec-
tively. Significant synergy was found for all isolates with mean FICi-0 values ranging from 0.28 to 0.75 (median, 0.46). Stronger
synergistic interactions were found with FICi-1 (median, 0.18; range, 0.07 to 0.47) and FICi-2 (0.31; 0.07 to 0.6). The FICi-2 val-
ues of isolates with tandem-repeat-containing mutations or codonM220 were lower than those seen with the other isolates (P<
0.01). FIC-2 values were inversely correlated with POSAMICs (rs0.52, P 0.0006) and linearly with the ratio of drug con-
centrations in combination over the MIC of POSA (rs 0.76, P< 0.0001) and CAS (rs 0.52, P 0.0004). The synergistic effect
of the combination of POSA and CAS (POSA/CAS) against A. fumigatus isolates depended on the underlying azole resistance
mechanism. Moreover, the drug combination synergy was found to be increased against isolates with elevated POSAMICs com-
pared to wild-type isolates.
The opportunistic fungal pathogen Aspergillus fumigatus hasbeen associated with several life-threatening infections in im-
munocompromised patients. Although azoles are the mainstay of
antifungal therapy, treatment of aspergillosis is a difficult task
which is further complicated by the lack of therapeutic efficacy in
infections due to multiply azole-resistant A. fumigatus (1–3).
Azoles are inhibitors of the 14- sterol demethylase in A. fu-
migatus, which is a product of cyp51A and cyp51B. Since the dis-
covery of these orthologs to the Candida albicans egr11 gene, a
number of single nucleotide polymorphisms (SNPs) have been
found, several of which have been associated with elevated azole
MICs in vitro, corresponding to treatment failure in vivo (1, 4–7).
It is believed that SNPs may develop through azole treatment or
through exposure to azole fungicides in the environment (8–10).
Treatment-induced SNPs in cyp51A aremainly allocated at codon
38, 54, or 220, while fungicide-induced SNPs aremostly located at
codon 98, usually combined with tandem repeats within the pro-
moter (8–10). Very recently, a new environmental azole resistance
mechanism consisting of TR46/Y121F/T289A was reported to be
associated with voriconazole treatment failure in patients with
invasive aspergillosis (11, 12).
Regardless of the factor that triggers the development of SNPs
in cyp51A, no tradeoff between resistance and loss of virulence has
been observed (13). Indeed, animal experiments performed with
isolates harboring cyp51A-mediated resistance mechanisms and
the numerous reported cases of acute pulmonary aspergillosis,
central nervous system aspergillosis, and disseminated disease in-
dicate that resistant mutants retain their virulence properties
(1–3, 14, 15).
The increased emergence of resistance has reduced the already
limited repertoire of available antifungal agents against aspergil-
losis, thereby necessitating the need for developing new treatment
alternatives. In recent years, combination therapy has been gain-
ing interest and popularity, as this can enhance therapeutic effi-
cacy and broaden the antifungal spectrum (16).
Although posaconazole is mainly proposed as a prophylactic
against fungal infections, in a recent monocentric and retrospec-
tive study, the combination of caspofungin and POSA was sug-
gested as a therapeutic regimen for effective and tolerable treat-
ment of invasive aspergillosis in immunocompromised patients
with disease refractory to primary treatment (17). Moreover, in
vitro and in vivo studies showed synergy between POSA and CAS
against A. fumigatus wild-type strains (18, 19). Lepak and col-
leagues, however, showed that therapy using a combination of
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POSA and CAS (POSA/CAS) in vivo did not enhance efficacy for
POSA-susceptible isolates but produced synergistic activity
against two POSA-resistant isolates (20).
Whether the interaction of POSA/CAS activity against azole-
resistant isolates is specific and hence is dependent on the under-
lying mechanisms of resistance or on the MIC factor is unknown.
Therefore, the goal of the present study was to investigate the in
vitro interactions of this drug using clinical A. fumigatus isolates
with a wide range of azole MICs and, most importantly, with
different resistance mechanisms.
MATERIALS AND METHODS
Clinical isolates. A total of 20 clinical A. fumigatus isolates were selected
based on the azole resistance mechanisms (Table 1). Three isolates were
defined as wild type (isolates AZN 8196, v52-76, and v28-29) on the basis
of the in vitro susceptibility profile and the lack of mutations in cyp51A.
Thirteen isolates were defined as non-wild type on the basis of the in vitro
susceptibility profile and the presence of mutations in cyp51A that have
been shown to be associated with azole resistance. Three isolates (v52-35,
v45-07, and v61-76) harbored the TR34/L98H resistance mechanism, two
isolates (v94-10 and v107-65) harbored TR46/Y121F/T289A, and one iso-
late (v49-29) harbored TR53. Four isolates harbored substitutions at
codon M220 (M220I, isolate v28-77; M220V, v13-09; M220K, v59-07;
and M220R, 3038), two isolates a substitution at codon G54 (G54W,
v59-73 and v79-25), and one isolate a substitution at codonG138 (G138C,
isolate v59-72).
In addition, four isogenic A. fumigatus isolates (isolates S1, S2, R1,
and R2) were used that were cultured serially from a single patient with
chronic granulomatous disease (21). The patient failed azole-echino-
candin therapy for treatment of chronic pulmonary Aspergillus infec-
tion. At the outset of treatment, the first two recovered isolates (S1 and
S2) showed a wild-type profile; however, after 2 years of therapy, the
next two isolates (R1 and R2) gained properties of resistance to all
azoles. Despite elevated expression of cyp51A in isolates R1 and R2
compared to the S1 and S2 isolates, no SNPs were found in cyp51A,
indicating regulation of cyp51A by the HapE resistance mechanism
(21, 22). In fact, the novel resistance mechanism was caused by a P88L
substitution in CCAAT-binding transcription factor complex subunit
HapE (22).
As previously described, all isolates were stored at80°C and subcul-
tured (23, 24). All A. fumigatus isolates were identified based on the mor-
phological characteristics and sequencing of the -tubulin and calmodu-
lin genes, as described previously (7). The cyp51A coding region and its
promoter were sequenced as previously described (5, 25). Candida krusei
ATCC 63058, C. parapsilosis ATCC 22019, and A. fumigatus MYA3561
were used as quality controls.
Susceptibility testing.Antifungal susceptibility testingwas performed
based on the M38-A2 method of the Clinical and Laboratory Standards
Institute (CLSI) (26). The drug interaction assay was performed using an
8-by-12-square checkerboard design, as previously described (27). POSA
and CAS concentrations ranged from 8 to 0.002 mg/liter and from 4 to
0.06 mg/liter, respectively. Fungal growth was assessed using spectropho-
tometry with the modified XTT [2,3-bis (2-methoxy-4-nitro-5-sulfophe-
nyl)-2H-tetrazolium-5-carboxanilide inner salt] method after incubation
for 48 h, as described previously (28, 29). The MIC of POSA and the
minimal effective concentration (MEC) of CAS were determined as the
lowest concentration showing complete inhibition (90%) and partial
inhibition (50%; MIC-2) of growth (27). All experiments were per-
formed in three independent replicates.
Pharmacodynamic interaction analysis. The synergistic, additive, or
antagonistic effect of paired (or more) combinations of drugs was cap-
tured by the fractional inhibitory concentration (FIC) index (FICi). This
numerical value is calculated by the summation of the FIC for each drug
(drugs A and B), where the FIC is determined by dividing the MIC of the
TABLE 1 MICs of posaconazole and MECs of caspofungin based on the CLSI-M38A2 methodologya
Isolate ID Disease Mutation(s)c
Visual reading
POSA MIC
(mg/liter)
CAS MEC
(mg/liter)
v52-35 Proven invasive aspergillosis TR34/L98H 0.5 1
v45-07 Proven invasive aspergillosis TR34/L98H 1 1
v61-76 Proven invasive aspergillosis TR34/L98H 0.5 1
v094-10 Proven invasive aspergillosis 46/TR 0.25 0.5
v107-65 Proven CNS aspergillosis 46/TR 1 1
v049-29 Proven Aspergillus osteomyelitis 53/TR 0.5 1
v059-73 Clinical isolate (unknown entity) G54W 8 1
v079-25 Clinical isolate (unknown entity) G54W 8 1
3038 Proven invasive aspergillosis M220R 8 0.25
v28-77 Aspergilloma M220I 1 1
v59-27 Allergic pulmonary aspergillosis M220K 16 1
v13-09 Probable invasive aspergillosis M220V 1 1
v59-72 Aspergilloma G138C 8 1
AZN 8196 Proven invasive aspergillosis — 0.06 0.5
v52-76 Proven invasive aspergillosis — 0.06 1
v28-29 Proven invasive aspergillosis — 0.06 1
v67-38 (S1)b Chronic pulmonary aspergillosis — 0.06 1
v67-37 (S2)b Chronic pulmonary aspergillosis — 0.125 1
v67-36 (R1)b Chronic pulmonary aspergillosis HapE/P88L 0.5 1
v67-35 (R2)b Chronic pulmonary aspergillosis HapE/P88L 0.5 1
a ID, identifier; MEC, minimal effective concentration.
b These four isolates were cultured consecutively from a single patient (21). Two isolates exhibited a wild-type (WT) susceptibility profile (S1 and S2), while two were azole resistant
(R1 and R2). Microsatellite genotyping of all four isolates showed identical genotypes. No cyp51A mutations were found, but a P88L substitution in the CCAAT-binding
transcription factor complex subunit HapE seemed to be responsible for the azole-resistant profile (22).
c —, no mutations in cyp51A and/or hapE.
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combination of two drugs (drug A plus drug B) by the MIC of each drug
alone as follows:
a) FICA
MICAB
MICA)
b) FICB
MICAB
MICB)
c) FICi FICA FICB
If the FICi FICmin value is lower than 1, this indicates synergistic
interaction between two drugs; if the FICi FICmax value is higher than
1.25, then an antagonistic interaction exists, while the additivity range is
within FICmin values and FICmax values of 1 to 1.25. In the current
study, the fractional inhibitory concentration index was assessed as
CPOSA/MICPOSA  CCAS/MICCAS, where MIC and C are the concentra-
tions of POSA and CAS alone and in combination, respectively, corre-
sponding to at least 10% (FICi-0), 25% (FICi-1), or 50% (FICi-2) of
growth. The different endpoints of fungal growth were used in order to
assess pharmacodynamic interactions at low (FICi-2), intermediate
(FICi-1), and higher (FICi-0) drug concentrations. To capture both syn-
ergistic and antagonistic interactions, the FICmin and FICmax were calcu-
lated as the minimum and maximum FICi for each isolate and replicate.
Synergy and antagonism were concluded when the log2 FICi values of the
three independent replicates were statistically significantly (P  0.05)
lower than 1 and higher than 1.25, respectively, by Student’s t test as
proposed previously based on in vitro-in vivo correlation studies (30). In
any other case, an additive effect was claimed.
Isolates were categorized into 5 groups based on their genetic and
phenotypic characteristics as follows: (i) a wild-type group harboring nei-
ther cyp51A nor hapEmutations and demonstrating low MIC values; (ii)
ATR group of isolates containing tandem repeats in the promoter (the TR
group can be also referred to as the environmental resistance group be-
cause of its reported relationshipwith development of azole resistance due
to pesticides [see introduction]); (iii) a M220 group which contained
diverse substitutions at codon M220 and which were found in patients
only after prolonged treatment; (iv) a G54W and G138C group (G/W)
recovered from patients after prolonged azole treatment; and (v) a HapE
group to be used as a control given the identical genetic backgrounds as
well as the previously reported very low growth rate. Using these groups,
we aimed to determine whether the FIC can be affected by a slow-growth
phenotype.
Analysis.To associate in vitro interactions with azole resistancemech-
anisms, the FICis of the isolates from each group were compared using
analysis of variance followed by Bonferroni’s multiple-comparison test.
To explore whether in vitro interactions were dependent on in vitro sus-
ceptibility to POSA and CAS, FICis were correlated with POSA and CAS
MICs by Spearman correlation analysis. Similarly, in vitro interactions
were also correlatedwith drug concentrations in synergistic combinations
corresponding to the FICmin as absolute concentrations and as multiples
of MICs after calculation of the drug concentration in combination/MIC
ratio. All replicates were analyzed individually. Approximated FICs calcu-
lated from off-scale MICs were excluded from the analysis.
RESULTS
The results of FICi analysis for three growth levels are shown in
Table 1, where the median and range of the MICs of the drugs
alone, the FICmin, and the FICmax and the drug concentrations in
combination are shown. The MIC (10% growth endpoint) of
POSA was 0.06 (range, 0.03 to 0.06) mg/liter for the wild-type
isolates, whereas higher MICs were found for isolates harboring
the tandem repeats (TR group), namely, the M220, G54W, and
G138C mutations, for which the MICs were 0.5 (range, 0.25 to 1)
mg/liter, 1 (0.5 to 4)mg/liter, and 0.25 (0.06 to 4)mg/liter, respec-
tively, and the S1 and S2 isolates without mutations in cyp51A, for
which the MIC was 0.13 (0.06 to 0.5) mg/liter. The median CAS
MEC (50% growth endpoint) ranged from 0.5 to 1 mg/liter for
all isolates.
Pharmacodynamic interactions. The FICimins for all isolates
and growth endpoints were significantly lower than 1, indicating
synergy (P  0.05) (Table 2). None of the FICimaxs were signifi-
cantly higher than 1.25, indicating that no antagonism was ob-
served (data not shown). The lowest FICimins were found at the
25%growth endpoint for all three groups of isolates, with FICimins
ranging from 0.06 to 0.76. Statistically significant differences be-
tween the four groups of isolates were found at the 50% growth
endpoint, where the lowest FICimins were found for isolates of the
M220 group (0.13 [range, 0.05 to 0.5]mg/liter) followed by theTR
group (0.27 [0.08 to 0.76] mg/liter) and the HapE isolates (0.25
[0.13 to 0.62] mg/liter) (Fig. 1).
TABLE 2 Results of FIC index analysis based on 50%, 25%, and 10% growth endpoints for each group of A. fumigatus azole-resistant and azole-
susceptible isolates harboring different or no mutations in cyp51A
Growth
endpoint (%) Isolates
FIC index (range)
Drugs alone Drugs in combinations
MICPOSA MICCAS FICimin
a CPOSA CCAS
50 Wild types 0.03 (0.02–0.03) 0.5 (0.5–1) 0.44 (0.19–1.06)* 0.01 (0.01–0.02) 0.13 (0.06–0.5)
TR group 0.13 (0.01–0.5) 0.5 (0.25–1) 0.27 (0.08–0.76)* 0.01 (0.01–0.06) 0.06 (0.06–0.5)
M220 group 4 (0.02–4) 1 (0.5–8) 0.13 (0.05–0.5)* 0.01 (0.01–1) 0.13 (0.06–1)
G54/G138 4 (0.01–4) 0.5 (0.13–2) 0.5 (0.13–0.56)* 0.01 (0.01–0.25) 0.06 (0.06–0.5)
HapE 0.03 (0.01–0.13) 1 (0.5–8) 0.25 (0.13–0.62)* 0.01 (0.01–0.03) 0.13 (0.06–1)
25 Wild types 0.05 (0.03–0.06) 8 (1–8) 0.22 (0.09–0.76)* 0.01 (0.01–0.02) 0.5 (0.13–2)
TR group 0.5 (0–1) 8 (1–8) 0.13 (0.06–0.52)* 0.01 (0.01–0.13) 0.5 (0.06–1)
M220 group 4 (0.25–4) 8 (1–8) 0.25 (0.07–0.5)* 0.02 (0.01–0.25) 1 (0.5–2)
G54/G138 4 (0.06–4) 5 (0.5–8) 0.2 (0.06–1)* 0.01 (0.01–0.13) 0.5 (0.06–1)
HapE 0.13 (0.03–0.5) 8 (2–8) 0.16 (0.06–0.62)* 0.01 (0.01–0.03) 0.5 (0.13–2)
10 Wild type 0.06 (0.03–0.06) 8 (8–8) 0.53 (0.38–0.64)* 0.02 (0.01–0.03) 1 (0.06–2)
TR group 0.5 (0.25–1) 8 (8–8) 0.52 (0.25–0.75)* 0.13 (0.06–0.5) 1 (0.13–2)
M220 group 1 (0.5–4) 8 (8–8) 0.63 (0.31–0.75)* 0.25 (0.25–0.5) 2 (1–2)
G54/G138 0.25 (0.06–4) 8 (8–8) 0.25 (0.19–1.02)* 0.06 (0.03–1) 1 (0.06–2)
HapE 0.13 (0.06–0.5) 8 (8–8) 0.5 (0.28–0.56)* 0.06 (0.02–0.13) 0.5 (0.25–2)
a *, P 0.05.
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Drug concentrations. The synergistic interactions at the 10%
growth endpoint (MIC effect level) were found at median POSA
concentrations of 0.02 mg/liter for wild-type isolates, 0.13 and
0.25 mg/liter for the TR group andM220 group, respectively, and
0.06 mg/liter for the G54W and G138C group and HapE isolates
(Table 1), which corresponded to 0.25 to 0.5MIC for all iso-
lates irrespective of the MICs. At higher growth endpoints (sub-
MIC effect levels), lower drug concentrations (0.25 MIC)
were required to show a synergistic effect. The median CAS con-
centrations of the synergistic interactions at the 50% growth end-
point (MEC effect level) were 0.06 to 0.13 mg/liter and corre-
sponded to 0.125 to 0.25 MEC. At lower growth endpoints
(supra-MEC effect level), the synergistic interactions were found
at concentrations of 0.5 to 2 mg/liter, which corresponded to the
MEC of CAS (Table 1). In Fig. 2, three checkerboard data are
shown for three A. fumigatus isolates, 1 wild type and 2 with dif-
ferent azole resistancemechanisms (TR34/L98H andM220), dem-
onstrating similar FIC-0mins but different FIC-2mins. The drug
concentrations where these synergistic interactions occur can be
visualized for each drug and growth endpoint.
Correlation of FICs with MICs and drug concentrations in
combinations. The FICi-2 values but not FICi-0 values and
FICi-1 values were significantly correlated with POSAMICs (rs	
0.52, P	 0.0004), as shown in Fig. 3. No significant correlation
was found with the 50% growth CAS MIC (MIC-2) values (rs 	
0.17, P	 0.25). When drug concentrations in synergistic com-
bination were analyzed as multiples of MIC but not as absolute
concentrations, significant correlations between FICi-2s and
POSA (rs	 0.76, P	0.0001) and CAS (rs	 0.52, P	 0.0004)
concentration/MIC-2 ratios were found (Fig. 4). In general, FICs
lower than 0.25 corresponded to drug concentration/MIC ratios
lower than 0.5.
DISCUSSION
Thepresent study investigated the potential synergismof the com-
bination of POSA and CAS against strains with different azole-
resistant mechanisms and different POSA MICs. We used strains
with singlemutations in cyp51A or hapEwhich were isolated from
patients with proven aspergillosis subjected to azole therapy (1,
21, 31, 32). In addition, we used a set of azole-resistant strains
isolated from patients who were potentially infected through in-
halation from the environment (33–35). These environmental az-
FIG 1 Graphical representation of FICimins determined at 10%, 25%, and 50% of growth. Five groups are presented: (i) the azole-susceptible group (wild type
[WT])withmutations neither in cyp51Anor in hapE, (ii) the azole-resistant TR group (TR34/L98H,TR46/Y121F/T289A, TR53/L98), (iii) the azole-resistantM220
group (M220V,M220K,M220I,M220R), (iv) the azole-resistantG/Wgroup (G138C andG54W), and (v) the isogenic group consisting of the two azole-resistant
R1 andR2 strainswith substitutions in hpaE. The parental S1 and S2 azole-susceptible strains fromR1 andR2were added to theWTgroup. Significant differences
were found at the 50% growth endpoint, with the strongest synergy found for isolates harboring the M220 mutation.
FIG 2 Checkerboard of the POSA/CAS combination with an azole-suscepti-
ble A. fumigatus wild-type isolate (top checkerboard) and two azole-resistant
A. fumigatus isolates harboring TR34/L98H (middle checkerboard) and M220
(bottom checkerboard) mutations in cyp51A. Note that the FICi-0min values
(0.504, 0.376, and 0.5) were not significantly different, whereas significant
differences were found for FICi-2min (1.064, 0.311, and 0.125) for the three
isolates, respectively. Numbers inside the checkerboard cells represent per-
centages of fungal growth assessed with the modified XTT methodology,
whereas the intensities of background color represent the three growth end-
points (10%, white;25%, light gray;50%, dark gray).
Synergy Posaconazole Caspofungin
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ole-resistant strains carried different numbers of tandem repeats
in the promoter of cyp51A (10, 33).
We found that the combination of POSA/CAS was synergistic
against all A. fumigatus isolates. Note that synergism between
POSA and CAS was identified not only in A. fumigatus but also in
Zygomycetes and Candida spp. (36–38). The previously reported
FICi of 0.32 against azole-susceptible A. fumigatus was similar to
the FICi found in the present study.
In the current study, however, POSA/CAS synergy in isolates
with cyp51A-mediated azole resistance revealed unexpected dif-
ferences in drug interactions between the different resistance
mechanisms and MICs. Interestingly, the strongest synergy was
found for the group of isolates harboring the tandem repeats at the
promoter region of cyp51A and for the groupwith substitutions at
the M220 hot spot region. Our results are supported by a murine
model of pulmonary aspergillosis in which POSA monotherapy
andCASmonotherapy demonstrated suboptimal outcomes (40%
to 50% survival); however, the drug combination led to enhanced
efficacy (70% to 80% survival), mostly for the groups infected
with POSA-resistant isolates with drug MICs of 2 and 8 mg/liter,
respectively (20). These two resistant isolates were also reported to
contain G138C and TR34/L98H mutations in cyp51A.
To the best of our knowledge, drug synergy that is dependent
on the resistance mechanism has not yet been reported for fungi.
Although a marked synergistic effect between POSA and CAS was
demonstrated in previous investigations, the mechanism of this
remains unclear (18, 37). Our data show that the POSA MIC is a
major determinant of the strength of the synergistic interaction
and that this synergistic effect is concentration dependent, with
strong interactions observed at concentrations of0.5MIC. In
order to explain the synergistic interaction between POSA and
CAS, Guembe et al. suggested that the inhibition of ergosterol
biosynthesis by POSA may change the membrane, making the
FKS1 enzyme more accessible or sensitive to inhibition by CAS
(37). They also suggested that cell wall alterations by CAS may
facilitate the penetration of POSA into the cell (37). Although
these hypotheses may explain the synergistic azole-echinocandin
interaction, they do not explain the differential synergistic inter-
actions of the POSA/CAS combination that depend on the azole
resistancemechanism inA. fumigatus. This phenomenon could be
explained by specific qualitative or quantitative modifications of
membrane sterols directly altering the membrane and indirectly
altering the cell wall function. Recently, Alcazar-Fuoli et al. inves-
tigated the sterol composition of azole-susceptible and azole-re-
sistant A. fumigatus strains (39). Resistance in these mutants de-
veloped due to deficiencies in different enzymatic steps of the
ergosterol biosynthesis pathway (Cyp51A, Cyp51B, Erg3A, Erg3B,
andErg3C). The analysis showed that, althoughmembrane sterols
of azole-resistantA. fumigatus strainswere qualitatively and quan-
titatively similar to those of the susceptible strains, the relative
compositions differed, depending on the deficient enzyme (39).
This indicates that alterations in the fungalmembrane sterol com-
position may lead to differential penetration characteristics of
azoles, thereby affecting POSA/CAS interaction. Yet further stud-
ies of membrane and cell wall changes performed using isolates
carrying the substitutions presented in this paper will shed further
light on the mechanism of azole resistance and POSA/CAS drug
synergy. Earlier reports proposed that azole resistance developed
FIG 3 Correlation between FIC indices and posaconazole MICs. rs	 Spearman correlation coefficient.
FIG 4 Correlation between FICi-2s of POS/CAS combination and POSA (left graph) and CAS (right graph) concentrations over MIC-2 ratio. rs	 Spearman
correlation coefficient. posa, posaconazole; cas, caspofungin.
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by cyp51A substitutions was associated with a lack of or a reduced
drug binding affinity to the 14a-demethylases due to altered
amino acids close to the heme factor (40). However, the authors
reported that the enzyme activity of azole-resistant isolates was
not affected despite the low affinity to azoles. Thus, ergosterol is
still produced in cyp51Amutants, most likely by the same or other
enzymes activated in order to overcome stress situations and to
preserve survival. These changes of fungal membrane sterol com-
position caused by azoles may also affect the 1,3--D-glucan syn-
thetase function and thereby the CAS activity.
Furthermore, in a murine model of disseminated aspergillosis,
although increased area under the concentration-time curve
(AUC) plasma concentration values were associated with in-
creased survival in the groups infected with the TR34/L98H and
M220I isolates (MIC 	 0.5 mg/liter), the G54W-infected groups
(MIC 16 mg/liter) showed no improved response (23). Appar-
ently, this occurs because the heme factor in G54W mutants is
completely blocked, thereby preventing access for POSA (41). In-
terestingly, the current in vitro study showed that even this obsti-
nate POSA-resistant isolate was significantly inhibited with the
combination of POSA/CAS, reaching an FIC similar to that ob-
served in wild-type isolates.
Additionally, we recently found that acquisition of azole resis-
tance mechanisms by A. fumigatus is sometimes associated with a
fitness penalty in terms of slow growth (13). To determine the
relationship between virulence and fungal growth, 15 of the 20
strains involved in the current study were used (13). That investi-
gation revealed a strong relationship between in vivo virulence and
in vitro fungal-growth-curve parameters, leading to the develop-
ment of a novel mathematical model which is able to predict vir-
ulence based on in vitro growth characteristics. One of three TR34/
L98H strains and isolates harboring M220K were slower growers
than other isolates with either identical or nonidentical mutations
andwere consequently less virulent.However, the slowest growers
in vitrowhich also demonstrated the lowest virulence in vivowere
the two HapE isolates. Intriguingly, although the HapE strains
were the slowest growers of the 20 isolates, we did not find a
POSA/CAS synergy similar to that of the M220I or TR groups. In
fact, the POSA/CAS effect on the HapE isolates revealed no signif-
icant synergistic difference from the wild-type group, indicating
that the growth rate did not play a role in this unique drug inter-
action phenomenon.
Understanding of the acquired azole resistance mechanisms
may be important to increase treatment efficacy. Overall, the cur-
rent study demonstrated that POSA at concentrations ranging
from 0.002mg/liter to 0.1mg/liter combinedwith CAS at concen-
trations from 0.06 to 0.13 mg/liter resulted in 50% reduction of
growth. What is of great interest is that these levels of both drugs
are clinically achievable and that the combination may therefore
be clinically useful for treatment of azole-resistant aspergillus dis-
eases (42, 43).
REFERENCES
1. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS,
Denning DW. 2006. Multi-azole resistance in Aspergillus fumigatus. Int J
Antimicrob Agents 28:450–453. http://dx.doi.org/10.1016/j.ijantimicag
.2006.08.017.
2. Howard SJ, Cerar D, Anderson MJ, Albarrag A. 2009. Frequency and
evolution of azole resistance inAspergillus fumigatus associated with treat-
ment failure. Emerg Infect Dis 15:1068–1076. http://dx.doi.org/10.3201
/eid1507.090043.
3. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant
aspergillosis. N Engl J Med 356:1481–1483. http://dx.doi.org/10.1056
/NEJMc061720.
4. Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D,
DiDomenico B, Hare RS, Walker SS, McNicholas PM. 2003. Mutations
in Aspergillus fumigatus resulting in reduced susceptibility to posacona-
zole appear to be restricted to a single amino acid in the cytochrome P450
14alpha-demethylase. Antimicrob Agents Chemother 47:577–581. http:
//dx.doi.org/10.1128/AAC.47.2.577-581.2003.
5. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL.
2001. Identification of two different 14-alpha sterol demethylase-related
genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus
species. J Clin Microbiol 39:2431–2438. http://dx.doi.org/10.1128/JCM
.39.7.2431-2438.2001.
6. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodri-
guez-Tudela JL. 2004. Substitutions at methionine 220 in the 14alpha-sterol
demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resis-
tance in vitro to azole antifungal drugs. Antimicrob Agents Chemother
48:2747–2750. http://dx.doi.org/10.1128/AAC.48.7.2747-2750.2004.
7. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA,
Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of
azole resistance in Aspergillus fumigatus and spread of a single resistance
mechanism. PLoS Med 5:e219. http://dx.doi.org/10.1371/journal.pmed
.0050219.
8. Snelders E, Huis In ’t Veld RA, Rijs AJ, Kema GH, Melchers WJ,
Verweij PE. 2009. Possible environmental origin of resistance of Aspergil-
lus fumigatus tomedical triazoles. Appl EnvironMicrobiol 75:4053–4057.
http://dx.doi.org/10.1128/AEM.00231-09.
9. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole
resistance in Aspergillus fumigatus: a side-effect of environmental fungi-
cide use? Lancet Infect Dis 9:789–795. http://dx.doi.org/10.1016/S1473
-3099(09)70265-8.
10. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee
SA. 2011. Azole resistance in Aspergillus fumigatus isolates from the
ARTEMIS global surveillance study is primarily due to the TR/L98Hmu-
tation in the cyp51A gene. Antimicrob Agents Chemother 55:4465–4468.
http://dx.doi.org/10.1128/AAC.00185-11.
11. Vermeulen E, Maertens J, Schoemans H, Lagrou K. 2012. Azole-
resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation
emerging in Belgium, July 2012. Euro Surveil 29:17:pii	20326. http:
//www.eurosurveillance.org/ViewArticle.aspx?ArticleId	20326.
12. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-
Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J,
Karawajczyk A, Zoll J, Melchers WJ, Verweij PE. 2013. Aspergillosis due
to voriconazole highly resistant Aspergillus fumigatus and recovery of ge-
netically related resistant isolates from domiciles. Clin Infect Dis 57:513–
520. http://dx.doi.org/10.1093/cid/cit320.
13. Mavridou E, Meletiadis J, Jancura P, Abbas S, Arendrup MC, Melchers
WJ, Heskes T, Mouton JW, Verweij PE. 2013. Composite survival index
to compare virulence changes in azole-resistantAspergillus fumigatus clin-
ical isolates. PLoS One 8:e72280. http://dx.doi.org/10.1371/journal.pone
.0072280.
14. Nascimento AM, Goldman GH, Park S, Marras SA, Delmas G, Oza U,
Lolans K, Dudley MN, Mann PA, Perlin DS. 2003. Multiple resistance
mechanisms among Aspergillus fumigatus mutants with high-level resis-
tance to itraconazole. AntimicrobAgents Chemother 47:1719–1726. http:
//dx.doi.org/10.1128/AAC.47.5.1719-1726.2003.
15. van der Linden JWM, Melchers WJG, Verweij PE, Jansen RR, Visser
CE, Geerlings SE, Bresters D, Kuijper EJ. 2009. Azole-resistant central
nervous system aspergillosis. Clin Infect Dis 48:1111–1113. http://dx.doi
.org/10.1086/597465.
16. Marr KA HS, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR,
Pappas P, Herbrecht R, Walsh TJ, Maertens J. 2012. A randomised,
double-blind study of combination antifungal therapy with voriconazole
and anidulafungin versus voriconazole monotherapy for primary treat-
ment of invasive aspergillosis, poster LB 2812. Abstr 22nd Eur Congr Clin
Microbiol Infect Dis.
17. Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kroger N,
Zander AR. Caspofungin plus posaconazole as salvage therapy of invasive
fungal infections in immunocompromised patients. Mycoses 54 (Suppl 1):
S39–S44.
18. Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D.
2006. Interaction between posaconazole and caspofungin in concomitant
Synergy Posaconazole Caspofungin
March 2015 Volume 59 Number 3 aac.asm.org 1743Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
treatment of mice with systemic Aspergillus infection. Antimicrob Agents
Chemother 50:2587–2590. http://dx.doi.org/10.1128/AAC.00829-05.
19. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Posaconazole
pharmacodynamic target determination against wild-type and Cyp51
mutant isolates of Aspergillus fumigatus in an in vivo model of invasive
pulmonary aspergillosis. Antimicrob Agents Chemother 57:579–585.
http://dx.doi.org/10.1128/AAC.01279-12.
20. Lepak AJ, Marchillo K, VanHecker J, Andes DR. 2013. Impact of in vivo
triazole and echinocandin combination therapy for invasive pulmonary
aspergillosis: enhanced efficacy against Cyp51 mutant isolates. Antimicrob
AgentsChemother 57:5438–5447. http://dx.doi.org/10.1128/AAC.00833-13.
21. Arendrup MC, Mavridou E, Mortensen KL, Snelders E, Frimodt-Moller
N, Khan H, Melchers WJ, Verweij PE. 2010. Development of azole
resistance in Aspergillus fumigatus during azole therapy associated with
change in virulence. PLoS One 5:e10080. http://dx.doi.org/10.1371
/journal.pone.0010080.
22. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA,
Verweij PE, Melchers WJ. 2012. Discovery of a HapE mutation that
causes azole resistance in Aspergillus fumigatus through whole genome
sequencing and sexual crossing. PLoS One 7:e50034. http://dx.doi.org/10
.1371/journal.pone.0050034.
23. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE.
2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus
isolates with mutations in the cyp51A gene. Antimicrob Agents Che-
mother 54:860–865. http://dx.doi.org/10.1128/AAC.00931-09.
24. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW.
2010. Impact of cyp51A mutations on the pharmacokinetic and pharma-
codynamic properties of voriconazole in a murine model of disseminated
aspergillosis. Antimicrob Agents Chemother 54:4758–4764. http://dx.doi
.org/10.1128/AAC.00606-10.
25. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, Melchers WJ, Verweij PE,
Cuenca-Estrella M, Rodríguez-Tudela JL. 2007. A new Aspergillus fumiga-
tus resistance mechanism conferring in vitro cross-resistance to azole an-
tifungals involves a combination of cyp51A alterations. AntimicrobAgents
Chemother 51:1897–1904. http://dx.doi.org/10.1128/AAC.01092-06.
26. CLSI. 2008. Reference method for broth dilution antifungals susceptibil-
ity testing of conidium-forming filamentous fungi: approved standard,
2nd ed.M38-A2. Clinical and Laboratory Standards Institute,Wayne, PA.
27. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Use
of high inoculum for early metabolic signalling and rapid susceptibility
testing of Aspergillus species. J Antimicrob Chemother 59:230–237. http:
//dx.doi.org/10.1093/jac/dkl488.
28. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly PJ, Verweij
PE. 2001. Comparison of spectrophotometric and visual readings of
NCCLSmethod and evaluation of a colorimetric method based on reduc-
tion of a soluble tetrazolium salt, 2,3-bis 2,3-bis [2-methoxy-4-nitro-5-
[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal
susceptibility testing of Aspergillus species. J Clin Microbiol 39:4256–
4263. http://dx.doi.org/10.1128/JCM.39.12.4256-4263.2001.
29. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij
PE. 2001. Colorimetric assay for antifungal susceptibility testing of asper-
gillus species. J Clin Microbiol 39:3402–3408. http://dx.doi.org/10.1128
/JCM.39.9.3402-3408.2001.
30. Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. 2004. In
vitro interactions between amphotericin B, itraconazole, and flucytosine
against 21 clinical Aspergillus isolates determined by two drug interaction
models. Antimicrob Agents Chemother 48:2007–2013. http://dx.doi.org
/10.1128/AAC.48.6.2007-2013.2004.
31. Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. Acquired
resistance to voriconazole and itraconazole in a patient with pulmonary
aspergilloma. Med Mycol 48:197–200.
32. Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning
DW. Efficacy and safety of posaconazole for chronic pulmonary aspergil-
losis. Clin Infect Dis 51:1383–1391.
33. Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F,
Verweij PE, Meis JF. 2014. Multi-azole-resistant Aspergillus fumigatus in
the environment in Tanzania. J Antimicrob Chemother 69:2979–2983.
http://dx.doi.org/10.1093/jac/dku259.
34. Vermeulen E, Lagrou K, Verweij PE. 2013. Azole resistance in Aspergillus
fumigatus: a growing public health concern. Curr Opin Infect Dis 26:493–
500. http://dx.doi.org/10.1097/QCO.0000000000000005.
35. Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van
der Lee HA, Klaassen CH, Melchers WJ, Verweij PE. 2012. Triazole
fungicides can induce cross-resistance to medical triazoles in Aspergillus
fumigatus. PLoS One 7:e31801. http://dx.doi.org/10.1371/journal.pone
.0031801.
36. Manavathu EK, Alangaden GJ, Chandrasekar PH. 2003. Differential
activity of triazoles in two-drug combinations with the echinocandin
caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 51:
1423–1425. http://dx.doi.org/10.1093/jac/dkg242.
37. Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. 2007.
Synergistic effect of posaconazole and caspofungin against clinical zygo-
mycetes. Antimicrob Agents Chemother 51:3457–3458. http://dx.doi.org
/10.1128/AAC.00595-07.
38. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF,
Redding SW. 2005. In vitro interaction of posaconazole and caspofungin
against clinical isolates ofCandida glabrata. Antimicrob Agents Chemother
49:3544–3545. http://dx.doi.org/10.1128/AAC.49.8.3544-3545.2005.
39. Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Lopez JF, Grimalt JO,
Cuenca-Estrella JM, Rodriguez-Tudela JL. 2008. Ergosterol biosynthesis
pathway in Aspergillus fumigatus. Steroids 73:339–347. http://dx.doi.org
/10.1016/j.steroids.2007.11.005.
40. Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. 1995. Mode of
action and resistance to azole antifungals associated with the formation
of 14 alpha-methylergosta-8,24 (28)-dien-3 beta,6 alpha-diol. Biochem
Biophys Res Commun 207:910–915. http://dx.doi.org/10.1006/bbrc.1995
.1272.
41. Snelders E, Karawajczyk A, Verhoeven RJ, Venselaar H, Schaftenaar G,
Verweij PE, Melchers WJ. 2011. The structure-function relationship of
the Aspergillus fumigatus cyp51A L98H conversion by site-directed mu-
tagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol
48:1062–1070. http://dx.doi.org/10.1016/j.fgb.2011.08.002.
42. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J,
Majithiya JB, Warn PA, Hope WW. 2011. Pharmacokinetics and phar-
macodynamics of posaconazole for invasive pulmonary aspergillosis: clin-
ical implications for antifungal therapy. J Infect Dis 203:1324–1332. http:
//dx.doi.org/10.1093/infdis/jir023.
43. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis
RE. 2004. Pharmacodynamics of caspofungin in a murine model of inva-
sive pulmonary aspergillosis: evidence of concentration-dependent activ-
ity. J Infect Dis 190:1464–1471. http://dx.doi.org/10.1086/424465.
Mavridou et al.
1744 aac.asm.org March 2015 Volume 59 Number 3Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
